Ultragenyx Pharmaceutical (RARE) Work In Process (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Work In Process data on file, last reported at $33.0 million in Q1 2026.

• On a quarterly basis, Work In Process rose 44.02% year-over-year to $33.0 million in Q1 2026; TTM through Mar 2026 was $33.0 million, a 44.02% increase from a year earlier, with the FY2025 full-year figure at $27.0 million, up 22.73% from the prior year.
• Work In Process for Q1 2026 stood at $33.0 million, up from $27.0 million in the prior quarter.
• Over the last five years, Work In Process for RARE reached as high as $33.0 million in Q1 2026 and fell as low as $12.0 million in Q1 2022.
• Historically, Work In Process has averaged $20.9 million across 5 years, with a median of $19.8 million in 2025.
• Across the five-year window, Work In Process jumped 76.75% in 2022 and decreased 21.77% in 2025, its largest moves.
• Year by year, Work In Process stood at $17.5 million in 2022, then increased by 7.85% to $18.9 million in 2023, then gained by 16.66% to $22.0 million in 2024, then increased by 22.73% to $27.0 million in 2025, then increased by 22.22% to $33.0 million in 2026.
• Per Business Quant data, the three most recent Work In Process figures were $33.0 million in Q1 2026, $27.0 million in Q4 2025, and $29.2 million in Q3 2025.